Skip to main content
Premium Trial:

Request an Annual Quote

STMicroelectronics, Clonit, Italian Institute Develop Prototype POC Ebola MDx

NEW YORK(GenomeWeb) — STMicroelectronics, Clonit, and Italy's National Institute for Infectious Diseases Lazzaro Spallanzani said today that they have developed a prototype of a portable analyzer which runs an RT-qPCR-based Ebola assay.

The analyzer and assay use whole blood and take about 75 minutes to detect the presence of Ebola virus.

The partners said in a statement that the new device features an extractor element that purifies viral RNA from a few microliters of whole blood. The RNA is then reverse transcribed and amplified on a "stamp-sized silicon microchip" pre-loaded with reagents developed by Clonit, an Italian biotechnology firm that recently developed a quantitative PCR kit to detect the Ebolavirus Zaire strain. The Clonit reagents enable on-chip quantitative real-time PCR, potentially providing viral load data to clinicians. The device also features an optical reader which interfaces with a PC.

The chip and optical reader were contributed by STMicroelectronics, an international semiconductor manufacturer with corporate headquarters in Geneva. That company has IP around dielectrophoresis-based sample prep, a microfluidics chip, and on-chip real-time PCR. Its microfluidics technology also forms the basis for Veredus' VereFlu, VereTrop, and VereMERS assays.

The partners confirmed the sensitivity and accuracy of the new test with a blood sample diluted up to a million times, which could allow earlier detection of infection, and they are currently evaluating an integrated, self-contained, automated system that can run parallel analyses on a large number of samples.

A number of Ebola tests in development are attempting to break free from lab-based RT-PCR, including ones from IDT and Ubiquitome, BioFire Defense, Lucigen, and BioInnovation Solutions, with a number of these firms pursuing Emergency Use Authorization from the US Food and Drug Administration. 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.